American Society of Hirudotherapy

Smart Library

Faceted search across all 5 registries. Filter by registry type, evidence level, or safety domain.

Curated knowledge library: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.Reference collection: Content is historical, educational, or biographical reference material — not a clinical recommendation.

New to hirudotherapy? Start here

This library indexes the full evidence base. For orientation, begin with the core guides:

Conditions

12

Cervical Radiculopathy

Tier C

Investigational use for cervical radiculopathy; no verifiable published trial specific to this indication.

Investigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Mechanistic

Migraine

Tier C

Investigational use; the only clinical studies found in journal searches are a 7-patient case series and a 26-patient non-randomized pilot (older reports are described in “What the books describe”), and the proposed mechanism is hypothetical.

Investigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Mechanistic

Peyronie's Disease (Stable Phase)

Tier C

Investigational use for stable-phase Peyronie's disease; evidence limited to one uncontrolled Russian series of 29 patients. Standard treatments (verapamil, collagenase, surgery) remain first-line.

Investigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Mechanistic

Peripheral Vertigo (BPPV-Refractory / Vestibular Neuritis Recovery)

Tier C

Investigational adjunct for peripheral vertigo persisting after Epley maneuvers or during prolonged vestibular neuritis recovery; no study specific to these conditions was identified.

Investigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Mechanistic

Tarsal Tunnel Syndrome

Tier C

Investigational use for posterior tibial nerve entrapment at the medial ankle; no clinical study of leech therapy for it was identified.

Investigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Mechanistic

Pubic Symphysis Dysfunction (Non-Pregnancy)

Tier C

Investigational use for non-pregnancy pubic symphysis dysfunction, including osteitis pubis; no clinical study of leech therapy was identified.

Investigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Mechanistic

Cervicogenic Headache

Tier C

Investigational adjunct for cervicogenic headache referred from upper cervical (C1-C3) joints; no clinical study in diagnosed cases was identified.

Investigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Mechanistic

Chronic Anal Fissure (>8 Weeks)

Tier C

Investigational idea for chronic anal fissure refractory to medical therapy; no clinical study identified; sphincterotomy remains the gold standard.

Investigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Mechanistic

Multiple Sclerosis Fatigue (Investigational Adjunct)

Tier C

Investigational adjunct for MS-related fatigue; no clinical study was identified; disease-modifying therapy and modafinil/amantadine remain primary.

Investigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Mechanistic

Ramsay Hunt Syndrome (Investigational Adjunct, Convalescent Phase)

Tier C

Investigational adjunct for convalescent-phase Ramsay Hunt syndrome residual facial weakness; antiviral plus corticosteroid started within 72 hours of onset remains evidence-based.

Investigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Mechanistic

Buerger's Disease / Thromboangiitis Obliterans (Investigational Adjunct)

Tier C

Investigational adjunct for Buerger's disease; absolute tobacco cessation is the only disease-modifying intervention; iloprost and surgical sympathectomy for selected cases.

Investigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Mechanistic

Ischial Bursitis (Investigational Adjunct)

Tier C

Investigational adjunct for refractory ischial (ischiogluteal) bursitis; activity modification, hamstring loading, and selective injection remain primary.

Investigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Mechanistic

Compounds

52

Hyaluronidase

Enzyme that degrades hyaluronic acid in extracellular matrix — 'spreading factor' enhancing diffusion of other SGS compounds.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Ixodegrin (leech homolog)

Platelet GP IIb/IIIa antagonist family member — RGD-motif containing.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Kallikrein Inhibitor

Plasma kallikrein-kinin system modulator — anti-inflammatory pathway distinct from cyclooxygenase.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Nitric Oxide Synthase Modulator

Modulates host NOS activity at bite site — contributes to vasodilation phase of feeding.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Histamine-like Vasodilator

Histamine-receptor-acting compound — contributes to local vasodilation at feeding site.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Acetylcholine

Cholinergic vasodilator contributing to feeding-site vascular dilation.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Collagenase

ECM-degrading enzyme — facilitates spread of salivary compounds at the bite site.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Apyrase

ADP-degrading enzyme — prevents platelet aggregation by hydrolyzing ADP at bite site.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Tissue Factor Pathway Inhibitor

Inhibitor of tissue factor / Factor VIIa complex — blocks extrinsic coagulation pathway.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Thrombomodulin-binding factor

Modulates the thrombin-thrombomodulin axis — implications for protein C pathway.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech VEGF Modulator

Vascular endothelial growth factor pathway modulator — angiogenic and wound-healing implications.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech PDGF Modulator

Platelet-derived growth factor pathway modulator — implications for wound-healing.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Eicosanoid Modulator

Modulates prostaglandin and leukotriene cascades — anti-inflammatory pathway.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Bufrudin

Direct thrombin inhibitor from the Asian buffalo leech — hirudin homolog described in Hirudinaria manillensis secretome.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Haemadipsin

Anticoagulant peptide described in the terrestrial Asian leech Haemadipsa zeylanica.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Whitmanin

Direct thrombin inhibitor homolog cataloged in the Chinese medicinal leech Whitmania pigra secretome.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Piscicolin

Small direct thrombin inhibitor described in the fish leech Piscicola geometra secretome.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Macrobdellin

Anticoagulant peptide described in the North American medicinal leech Macrobdella decora.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Destabilase-2

Second isoform of destabilase — lysozyme / isopeptidase activity targeting cross-linked fibrin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Hirudinase

Alternate fibrin-cleaving enzyme reported in Hirudo medicinalis salivary secretions.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Collagenolytic Fibrinolysin

Dual-function protease degrading both fibrin clot scaffolds and collagen extracellular matrix.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Bradykinin Modulator

Salivary factor reported to modulate the bradykinin / kinin-kallikrein vasoactive cascade.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Substance P Modulator

Salivary factor reported to modulate the substance P / neurokinin-1 nociceptive pathway.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Granulin-A

Granulin-family peptide identified in Hirudo medicinalis — putative growth-factor / wound-healing analog (mechanistic only).

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Buccalin-Like Peptide

Putative neuroactive signaling peptide identified in leech salivary tissue — named by analogy to mollusc buccalin; function speculative.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Thrombin-Cleavable Peptide

Substrate-mimetic peptide segment identified in leech salivary transcriptome — putative thrombin substrate / competitive inhibitor variant.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Hirudo Lectin

Carbohydrate-binding lectin reported in Hirudo medicinalis salivary glands — putative agglutinin / immune modulator.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Saposin-Like Peptide

Saposin-like lipid-binding peptide identified in leech salivary transcriptome — putative membrane-active component.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Thrombospondin-Like Protein

Thrombospondin-type repeat (TSR)-domain protein identified in leech salivary transcriptome — putative platelet / matrix interactor.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Phospholipase A2 Inhibitor

Putative PLA2 inhibitor identified in leech salivary transcriptome — candidate eicosanoid-cascade modulator.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech C-Type Lectin

C-type lectin domain protein identified in Hirudo medicinalis salivary transcriptome — putative carbohydrate / glycoprotein binder.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

WP-Anticoagulant Genes (7-Transcript Family)

Whitmania pigra salivary anticoagulant gene family (Huang 2026 transcriptome) — seven coagulation-related transcripts including fibrinolytic enzymes, neutrophil-elastase inhibitors, factor Xa inhibitors.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Hirudin-Like Factors (HLFs)

Hirudin-paralog family lacking some structural hirudin features — Müller 2016 phylogenetic characterization across Hirudo and Hirudinaria genera.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Haemadipsa yanyuanensis Progranulin (Hy-PGRN)

Putative progranulin gene with 122 cysteine residues and nine tandem repeats — distinctive structural organization (Lin 2025 chromosome-level genome).

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Haemadipsa yanyuanensis Bdellin Expansion

Lineage-specific 8.7-25-fold expansion of bdellin protease-inhibitor gene family in H. yanyuanensis genome (Lin 2025) — candidate driver of terrestrial-blood-feeding adaptation.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Haemadipsa yanyuanensis LDTI Expansion

Lineage-specific expansion of LDTI (leech-derived tryptase inhibitor) gene family in H. yanyuanensis (Lin 2025) — candidate mast-cell modulator repertoire.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Hirudinaria manillensis Macins (Hman1/Hman2/Hman3)

Three macin antimicrobial peptide paralogs from Asian buffalo leech — Yu 2025 documents Hman1 functional, Hman2 / Hman3 partly pseudogenized.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Hirudinaria bpling Anticoagulant Family

Chromosome-level genome of H. bpling (Khan 2025) annotates 20+ anticoagulant gene families including 'Bplins' — a novel species-specific factor family.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Hni-Antistasin

Novel anticoagulant factor identified in the Hirudo nipponia salivary-gland transcriptome — Kim 2024 de novo assembly + in situ hybridisation.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Hni-Ghilanten

Novel ghilanten family anticoagulant in the Hirudo nipponia salivary-gland transcriptome — Kim 2024 spatial expression mapping.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Hni-Bdellin

Novel bdellin family Kazal-domain trypsin / plasmin inhibitor identified in the Hirudo nipponia salivary-gland transcriptome — Kim 2024.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Hni-GLIPR1

Previously unrecognized immune-related glioma-pathogenesis-related protein 1 homolog in the Hirudo nipponia salivary gland — Kim 2024.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

H. nipponia Starvation-Induced Salivary Proteome

181 differentially expressed proteins (72 up / 109 down) in starved Hirudo nipponia salivary glands — Cai 2024 proteomic + transcriptomic profiling.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

H. yanyuanensis Bdellin Family Expansion (2025)

8.7–25× lineage-specific expansion of the bdellin gene family in the terrestrial blood-feeding leech Haemadipsa yanyuanensis — Lin 2025 chromosome-level genome.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

H. yanyuanensis LCI Family Expansion (2025)

Lineage-specific expansion of the leech carboxypeptidase inhibitor (LCI) family in the terrestrial blood-feeding leech Haemadipsa yanyuanensis — Lin 2025.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

H. yanyuanensis Progranulin (122-Cys Variant)

Distinctive progranulin paralog with 122 cysteine residues + nine tandem repeats in the terrestrial blood-feeding leech Haemadipsa yanyuanensis — Lin 2025.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

H. verbana ERGA Chromosome-Level Anticoagulant Repertoire

First chromosome-level Hirudo verbana genome (14 pseudomolecules, 0.18 Gb, ERGA-BGE 2026) framing the southern medicinal leech as a primary genomic reference.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

W. pigra Chromosome-Level Genome (79 Antithrombotic Genes)

Chromosome-level W. pigra genome unexpectedly carries 79 antithrombotic genes — more than the 72 in blood-sucking H. manillensis (Liu 2024).

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Bloodsucking Leech FBN1 / GLB3 Expansion (Comparative)

Expanded FBN1 (fibrillin-1) + GLB3 (globin-3) gene families across H. nipponia / H. manillensis vs W. pigra — Zheng 2023 functional-genomic comparison.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Eglin C CTRL-Resistance Determinants

Structural determinants (Gln192, Lys218) explaining why eglin C, a classical broad-spectrum chymotrypsin / elastase inhibitor, poorly inhibits human chymotrypsin-like protease — Németh 2024.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Showing first 50 of 52. Refine filters to narrow results.

RCTs

9

Low-Level Antimicrobials in the Medicinal Leech Select for Resistant Pathogens That Spread to Patients

GRADE very low

Beka L, Fullmer MS, Colston SM, Nelson MC, Talagrand-Reboul E, Walker P, Ford B, Whitaker IS, Lamy B, Gogarten JP, Graf J (2018) · mBio

Mechanistic

Hirudins and hirudin-like factors in Hirudinidae: implications for function and phylogenetic relationships

GRADE very low

Müller C, Haase M, Lemke S, Hildebrandt JP (2016) · Parasitology Research

Mechanistic

Diversity of hirudin and hirudin-like factor genes in the North-African medicinal leech, Hirudo troctina

GRADE very low

Ahmed RB, Abilov A, Müller C (2024) · Parasitology Research

Mechanistic

Monomeric and Oligomeric Decorsins of the Asian Medicinal Leech

GRADE very low

Tolksdorf C, Wolf R, Rauch BH, Jedlitschky G, Müller C (2025) · International Journal of Molecular Sciences

Mechanistic

Molecular Insights into Leech-Derived Bioactive Compounds: Biochemical Mechanisms and Therapeutic Potential

GRADE very low

Raghavi S, Deva Darshini B, Saravanan KM, Anbarasu K (2026) · International Journal of Molecular Sciences

Mechanistic

Novel Sodium Channel Inhibitor From Leeches

GRADE very low

Wang G, Long C, Liu W, Xu C, Zhang M, Li Q, Lu Q, Meng P, Li D, Rong M, Sun Z, Luo X, Lai R (2018) · Frontiers in Pharmacology

Mechanistic

In-depth profiles of bioactive large molecules in saliva secretions of leeches determined by combining salivary gland proteome and transcriptome data

GRADE very low

Liu Z, Tong X, Su Y, Wang D, Du X, Zhao F, Wang D, Zhao F (2019) · Journal of Proteomics

Mechanistic

Salivary transcriptome of the North American medicinal leech, Macrobdella decora

GRADE very low

Min GS, Sarkar IN, Siddall ME (2010) · Journal of Parasitology

Mechanistic

Microbiota Dynamics: A Key Factor in Hirudotherapy-Related Infections?

GRADE low

Karasartova D, Arslan-Akveran G, Sensoz S, Mumcuoglu KY, Taylan-Ozkan A (2025) · Microorganisms

Mechanistic

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Smart Library — Faceted Search Across All Registries | ASH